161 related articles for article (PubMed ID: 29185022)
1. Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial.
Jensen KG; Gärtner S; Correll CU; Rudå D; Klauber DG; Stentebjerg-Olesen M; Fagerlund B; Jepsen JR; Fink-Jensen A; Juul K; Pagsberg AK
Psychopharmacology (Berl); 2018 Mar; 235(3):681-693. PubMed ID: 29185022
[TBL] [Abstract][Full Text] [Related]
2. Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial.
Jensen KG; Correll CU; Rudå D; Klauber DG; Decara MS; Fagerlund B; Jepsen JRM; Eriksson F; Fink-Jensen A; Pagsberg AK
J Am Acad Child Adolesc Psychiatry; 2019 Nov; 58(11):1062-1078. PubMed ID: 30858012
[TBL] [Abstract][Full Text] [Related]
3. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MG; Bilenberg N; Stenstrøm AD; Nyvang L; Madsen S; Werge TM; Lange T; Gluud C; Skoog M; Winkel P; Jepsen JRM; Fagerlund B; Correll CU; Fink-Jensen A
Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949
[TBL] [Abstract][Full Text] [Related]
4. CYP2D6 Genotyping and Antipsychotic-Associated Extrapyramidal Adverse Effects in a Randomized Trial of Aripiprazole Versus Quetiapine Extended Release in Children and Adolescents, Aged 12-17 Years, With First Episode Psychosis.
Rudå D; Jensen KG; Decara MS; Klauber DG; Fagerlund B; Møllegaard JR; Linnet K; Werge T; Correll CU; Fink-Jensen A; Jürgens G; Pagsberg AK
J Clin Psychopharmacol; 2021 Nov-Dec 01; 41(6):667-672. PubMed ID: 34735099
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone.
Gómez-Revuelta M; Pelayo-Terán JM; Juncal-Ruiz M; Ortiz-García de la Foz V; Vázquez-Bourgon J; González-Pinto A; Crespo-Facorro B
Int J Neuropsychopharmacol; 2018 Dec; 21(12):1090-1101. PubMed ID: 30215723
[TBL] [Abstract][Full Text] [Related]
6. Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial.
Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MB; Bilenberg N; Stenstrøm AD; Pedersen J; Nyvang L; Madsen S; Lauritsen MB; Vernal DL; Thomsen PH; Paludan J; Werge TM; Winge K; Juul K; Gluud C; Skoog M; Wetterslev J; Jepsen JR; Correll CU; Fink-Jensen A; Fagerlund B
BMC Psychiatry; 2014 Jul; 14():199. PubMed ID: 25015535
[TBL] [Abstract][Full Text] [Related]
7. Early Antipsychotic Nonresponse as a Predictor of Nonresponse and Nonremission in Adolescents With Psychosis Treated With Aripiprazole or Quetiapine: Results From the TEA Trial.
Pagsberg AK; Krogmann A; Jeppesen P; von Hardenberg L; Klauber DG; Jensen KG; Rudå D; Decara MS; Jepsen JRM; Fagerlund B; Fink-Jensen A; Correll CU; Galling B
J Am Acad Child Adolesc Psychiatry; 2022 Aug; 61(8):997-1009. PubMed ID: 35026408
[TBL] [Abstract][Full Text] [Related]
8. ECG parameters in children and adolescents treated with aripiprazole and risperidone.
Germanò E; Italiano D; Lamberti M; Guerriero L; Privitera C; D'Amico G; Siracusano R; Ingrassia M; Spina E; Calabrò MP; Gagliano A
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jun; 51():23-7. PubMed ID: 24211841
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study.
Savitz AJ; Lane R; Nuamah I; Gopal S; Hough D
J Am Acad Child Adolesc Psychiatry; 2015 Feb; 54(2):126-137.e1. PubMed ID: 25617253
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: a 12-week randomized, flexible-dose, open-label trial.
Crespo-Facorro B; Ortiz-García de la Foz V; Mata I; Ayesa-Arriola R; Suarez-Pinilla P; Valdizan EM; Vázquez-Barquero JL; Pérez-Iglesias R
Schizophr Res; 2013 Jul; 147(2-3):375-82. PubMed ID: 23643328
[TBL] [Abstract][Full Text] [Related]
11. Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1year study.
Crespo-Facorro B; Ortiz-Garcia de la Foz V; Suarez-Pinilla P; Valdizan EM; Pérez-Iglesias R; Amado-Señaris JA; Teresa Garcia-Unzueta M; Labad J; Correll C; Ayesa-Arriola R
Schizophr Res; 2017 Nov; 189():134-141. PubMed ID: 28223031
[TBL] [Abstract][Full Text] [Related]
12. Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis.
Pérez-Iglesias R; Ortiz-Garcia de la Foz V; Martínez García O; Amado JA; Garcia-Unzueta MT; Ayesa-Arriola R; Suarez-Pinilla P; Tabares-Seisdedos R; Crespo-Facorro B
Schizophr Res; 2014 Oct; 159(1):90-4. PubMed ID: 25151200
[TBL] [Abstract][Full Text] [Related]
13. Absence of Change in Corrected QT Interval in Children and Adolescents Receiving Antipsychotic Treatment: A 12 Month Study.
Alda JA; Muñoz-Samons D; Tor J; Merchán-Naranjo J; Tapia-Casellas C; Baeza I; Calvo-Escalona R; Castro-Fornieles J; Martínez-Cantarero C; Andrés-Nestares P; Fernández-Avilés F; Arango C
J Child Adolesc Psychopharmacol; 2016 Jun; 26(5):449-57. PubMed ID: 26779966
[TBL] [Abstract][Full Text] [Related]
14. Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis.
Vázquez-Bourgon J; Pérez-Iglesias R; Ortiz-García de la Foz V; Suárez Pinilla P; Díaz Martínez Á; Crespo-Facorro B
Psychopharmacology (Berl); 2018 Jan; 235(1):245-255. PubMed ID: 29075885
[TBL] [Abstract][Full Text] [Related]
15. A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers.
Kim A; Lim KS; Lee H; Chung H; Yoon SH; Yu KS; Cho JY; Jang IJ; Chung JY
Int Clin Psychopharmacol; 2016 Jul; 31(4):210-7. PubMed ID: 26950553
[TBL] [Abstract][Full Text] [Related]
16. Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study.
Molina L; Recinos B; Paz B; Rovelo M; Elias Rodriguez FE; Calderón J; Arellano A; Pomata S; Rey MV; Perez-Lloret S
Clin Drug Investig; 2016 Jun; 36(6):491-7. PubMed ID: 27021967
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study.
Hough DW; Natarajan J; Vandebosch A; Rossenu S; Kramer M; Eerdekens M
Int Clin Psychopharmacol; 2011 Jan; 26(1):25-34. PubMed ID: 20881844
[TBL] [Abstract][Full Text] [Related]
18. Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials.
Jensen KG; Juul K; Fink-Jensen A; Correll CU; Pagsberg AK
J Am Acad Child Adolesc Psychiatry; 2015 Jan; 54(1):25-36. PubMed ID: 25524787
[TBL] [Abstract][Full Text] [Related]
19. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.
Potkin SG; Preskorn S; Hochfeld M; Meng X
J Clin Psychopharmacol; 2013 Feb; 33(1):3-10. PubMed ID: 23277250
[TBL] [Abstract][Full Text] [Related]
20. Approach to Evaluating QT Prolongation of Quetiapine Fumarate in Late Stage of Clinical Development Using Concentration-QTc Modeling and Simulation in Japanese Patients With Bipolar Disorder.
Fukushi R; Nomura Y; Katashima M; Komatsu K; Sato Y; Takada A
Clin Ther; 2020 Aug; 42(8):1483-1493.e1. PubMed ID: 32792252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
